Halia Therapeutics, Inc

Halia Therapeutics, Inc Halia Therapeutics is focused on Leading the Science in Inflammation Drug Discovery

At Halia Therapeutics, we are discovering and developing novel therapies to improve the lives of patients with inflammatory disorders and neurological diseases. We do this by advancing innovative medicines that target the immune system’s response to resolve chronic inflammation and eliminate the damage caused by aberrantly activated immune responses. Founded in 2017, our incredible team of scienti

sts has worked tirelessly to bring Halia Therapeutics to the forefront in the field of inflammation drug discovery. We will continue to work relentlessly to translate our work into new medicines for patients.

Your muscles have a map, and it could be the secret to staying young! Scientists have created an "atlas of aging" that c...
08/08/2024

Your muscles have a map, and it could be the secret to staying young! Scientists have created an "atlas of aging" that could revolutionize how we fight muscle loss!

Read the details and learn more https://loom.ly/VbcgL-s

I’m excited to share that I will be attending the Global Health Exhibition 2024 this October. Join me in exploring healt...
08/07/2024

I’m excited to share that I will be attending the Global Health Exhibition 2024 this October. Join me in exploring healthcare innovations and connecting with industry experts.

Register Now: https://bit.ly/3yxFhOq

Halia Therapeutics CEO, Dr. David Bearss, will present data on a novel strategy targeting the assembly of the NLRP3 infl...
08/06/2024

Halia Therapeutics CEO, Dr. David Bearss, will present data on a novel strategy targeting the assembly of the NLRP3 inflammasome through NEK7 allosteric inhibition at the 3rd Edition Global Longevity Federation, held on August 12-13, 2024, in Rome, Italy!

Read the press release for more details https://loom.ly/CxPG_Ws

Exciting news in the fight against neurodegenerative diseases! Halia Therapeutics and Biolexis Therapeutics have teamed ...
07/31/2024

Exciting news in the fight against neurodegenerative diseases! Halia Therapeutics and Biolexis Therapeutics have teamed up to develop a new drug targeting NLRP3-driven neuroinflammation. This could be a game-changer for Parkinson's disease and other conditions.

Read the press release for more details: https://loom.ly/5nOurFs

Discover the link between aging and blood cell development in this groundbreaking study!Researchers explore the impact o...
07/30/2024

Discover the link between aging and blood cell development in this groundbreaking study!

Researchers explore the impact of clonal hematopoiesis, a process where blood stem cells acquire mutations, on the bone marrow and its aging process.

Learn about the potential implications for understanding and treating age-related diseases: https://loom.ly/_Wu8Ng8

Happy Pioneer Day!Let's honor the spirit of resilience and hard work that built our great state of Utah! Here at Halia T...
07/24/2024

Happy Pioneer Day!

Let's honor the spirit of resilience and hard work that built our great state of Utah! Here at Halia Therapeutics, we're committed to blazing new trails in healthcare.

Congratulations to CEO, Dr. David J. Bearss, on being recognized for his exceptional contributions to the pharmaceutical...
07/23/2024

Congratulations to CEO, Dr. David J. Bearss, on being recognized for his exceptional contributions to the pharmaceutical industry! His dedication and expertise are an inspiration to us all!

Learn more about his remarkable journey: https://loom.ly/fwyrLag

A Thrilling   in Madrid! Halia Showcases Advancements in HematologyThe vibrant city of Madrid hosted a fantastic  ! Dr. ...
07/22/2024

A Thrilling in Madrid! Halia Showcases Advancements in Hematology

The vibrant city of Madrid hosted a fantastic ! Dr. Margit Janat-Amsbury, our CMO, had the opportunity to attend and showcase Halia's latest research and advancements in hematology.

We were delighted to present our ongoing, promising trial for HT-6184, a NEK7/NLRP3 inflammasome inhibitor, in low-risk MDS at the congress.

View the abstract https://loom.ly/oL9hVRw

Dr. Janat-Amsbury enjoyed exchanging ideas with fellow hematology professionals and presenting our promising trial for HT-6184, a NEK7/NLRP3 inflammasome inhibitor, in low-risk MDS.

The congress featured insightful sessions, including Prof. Platzbecker's talk on MDS, Prof. Santini on Imetelstat, and the CHIP session on clonal hematopoiesis.

The role of the inflammasome across the disease spectrum was a key theme, highlighting exciting therapeutic opportunities!

Halia Therapeutics at the Utah Innovation Showcase!Halia Therapeutics was proud to be part of the Innovation Showcase at...
07/17/2024

Halia Therapeutics at the Utah Innovation Showcase!

Halia Therapeutics was proud to be part of the Innovation Showcase at the House Ways and Means Committee field hearing! We strongly believe in supporting initiatives that elevate Utah's thriving healthcare industry and the incredible innovators within it. This event was a fantastic example, and we were thrilled to participate!

Special thanks to Rep. Blake Moore (R-UT) for taking the time to stop by Halia's exhibit during his participation in the hearing!

Did you know scientists can now estimate how fast you're aging? A new test helps unlock the secrets of your biological a...
07/16/2024

Did you know scientists can now estimate how fast you're aging? A new test helps unlock the secrets of your biological age and the best part? There might be ways to slow it down! Check out this article by Allison Aubrey https://loom.ly/ZAxvlaY to learn more about this exciting research and what it means for your healthspan.

Did you know that Alzheimer's disease doesn't always start with memory loss? This article discusses the five different t...
07/11/2024

Did you know that Alzheimer's disease doesn't always start with memory loss? This article discusses the five different types of atypical Alzheimer's disease and the challenges of diagnosing them.

Learn more: https://loom.ly/5gxpBG8

Having two copies of the APOE4 gene is a strong risk factor for Alzheimer's disease, but it does not mean you will get i...
07/09/2024

Having two copies of the APOE4 gene is a strong risk factor for Alzheimer's disease, but it does not mean you will get it for sure! Estimates vary, but it increases your chances up to 60%. Some researchers consider it a genetic cause, not just a risk factor.

Read the details https://loom.ly/wEm1_Gc

Address

3900 N. Traverse Mountain Boulevard , Suite 100
Lehi, UT
84043

Telephone

+13853554315

Alerts

Be the first to know and let us send you an email when Halia Therapeutics, Inc posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share